US prevalence
~250,000 annual US procedures
Source: ASMBS 2022
Loading content…
Condition
Bariatric Pre- and Post-Op Support
GLP-1 therapy is increasingly used before bariatric surgery to optimize candidates and after surgery to manage weight regain. Use is off-label but rapidly growing in ASMBS practice. No GLP-1 is FDA-approved specifically for bariatric pre/post-op support. Off-label preoperative use can reduce liver volume and improve surgical access; off-label postoperative use addresses the roughly 25-30% of bariatric patients who experience clinically significant weight regain. Evidence grade: C (observational data growing; few RCTs). The ASMBS 2022 statement and emerging 2024-2025 consensus recognize this as an evolving practice. Pancreatitis and gastroparesis risks may merit extra caution in altered post-op anatomy.
Quick answer
UpdatedBariatric (weight-loss) surgery — gastric sleeve, RYGB, gastric bypass — is the most effective long-term weight-loss intervention (~30% body weight loss). GLP-1 medications complement surgery in three scenarios: (1) pre-op weight reduction to lower surgical risk, (2) post-op augmentation when weight loss stalls, (3) treatment of weight regain after surgery. Approximately 250,000 US bariatric procedures per year; ~25% of patients experience significant weight regain within 5 years.
- US annual procedures: ~250,000
- ASMBS 2022 estimates
- Average weight loss: ~30% body weight (long-term)
- STAMPEDE + SLEEVEPASS 5-year follow-up
- Weight regain rate: ~25% of patients within 5 years
- Variable by surgery type + patient factors
- GLP-1 pre-op role: Reduce surgical risk via 5-10% pre-op weight loss
- Common practice; varies by program
- GLP-1 post-op role: Address weight regain or insufficient loss
- Effective in observational studies